// App-Quantinova.ai

OP0275-PARE (2021) : THE UNACCEPTABLE DELAY TO DIAGNOSIS IN AXIAL SPONDYLOARTHRITIS; DEVELOPING A CALL TO ACTION FOR A GLOBAL HEALTHCARE CHALLENGE

Researchers

Presenter

  • W. Gerhart

Principal Investigators

  • M. T. Duruz

  • J. Lowe

  • D. Webb

  • J. Davies

  • R. Howard

  • M. Mallinson

Medical Centers

  • Canadian Spondylitis Association, Director, Toronto, Canada

  • Marmara University School of Medicine, Istanbul, Turkey

  • Axialspondyloarthritis International Federation, Executive, London, United Kingdom

  • National Axial Spondyloarthritis Society (NASS), Patient Advocacy, London, United Kingdom

  • Spafo Norge Spondyloartrittforbundet, Director, Oslo, Norway

  • Axialspondyloarthritis International Federation, Executive, London, United Kingdom

  • Spondylitis Association of America, Executive, Los Angeles, United States of America

  • Axialspondyloarthritis International Federation, Executive, London, United Kingdom

  • Arthritis Consumer Experts, Vancouver, BC, Canada

Locations

  • Canada

  • Turkey

  • United Kingdom

  • Norway

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Axial spondyloarthritis

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • UCB

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved